Tuesday, July 28, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 1,585 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 1,585
Companies 800
Drugs linked 4,222

Quick answer

NovaPharmaNews indexes 1,585 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 1 of 67
  1. WO 2026109729

    COMBINAISON COMPRENANT LE CAPIVASERTIB ET L'ABIRATÉRONE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE SENSIBLE AUX HORMONES (MHSPC) DÉFICIENT EN PTEN

    ASTRAZENECA AB [SE] · Granted May 28, 2026 · Expires May 23, 2046

    granted
  2. WO 2026078619

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  3. WO 2026078615

    ASSOCIATION DE TALAZOPARIB ET D'ENZALUTAMIDE DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE RÉSISTANT À LA CASTRATION

    PFIZER [US] · Granted Apr 16, 2026 · Expires Apr 11, 2046

    granted
  4. US 20260097057

    COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSIS

    ASTRAZENECA AB [SE] · Granted Apr 9, 2026 · Expires Apr 4, 2046

    granted
  5. WO 2026027669

    BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB

    ALFASIGMA SPA [IT] · Granted Feb 5, 2026 · Expires Jan 31, 2046

    granted
  6. US 20260027049

    AVACOPAN FORMULATIONS

    AMGEN INC [US] · Granted Jan 29, 2026 · Expires Jan 24, 2046

    granted
  7. US 12533358

    Methods of treatment with elinzanetant

    BAYER CONSUMER CARE AG [CH] · Granted Jan 27, 2026 · Expires Jan 22, 2046

    granted
  8. EP 4681704

    NEUE FORMULIERUNGEN VON PITOLISANT

    BIOPROJET PHARMA [FR] · Granted Jan 21, 2026 · Expires Jan 16, 2046

    granted
  9. WO 2026013310

    COMPOSITION PHARMACEUTIQUE LIQUIDE À BASE DE STIRIPENTOL

    BIOCODEX [FR] · Granted Jan 15, 2026 · Expires Jan 10, 2046

    granted
  10. WO 2025221754

    UPADACITINIB DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE L'ARTÉRITE À CELLULES GÉANTES

    ABBVIE INC [US] · Granted Oct 23, 2025 · Expires Oct 18, 2045

    granted
  11. US 2025295738

    Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin

    ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK] · Granted Sep 25, 2025 · Expires Sep 20, 2045

    granted
  12. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  13. US 12414942

    Compositions, methods, and systems for treating presbyopia

    LENZ THERAPEUTICS OPERATIONS, INC. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  14. US 12410184

    Crystalline forms of a menin inhibitor

    Kura Oncology, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  15. US 12404227

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  16. US 12403090

    Oral film compositions and dosage forms having precise active dissolution profiles

    Aquestive Therapeutics, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  17. US 12396963

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  18. US 12398087

    Methods of making bempedoic acid and compositions of the same

    Esperion Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  19. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  20. US 12390419

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    AXSOME MALTA LTD. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  21. US 12383545

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  22. US 12383512

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  23. US 12383535

    Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  24. US 12384743

    Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof

    AXSOME MALTA LTD. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 1,585 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.